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Abstract
Lipidomics is of increasing interest in studies of biological systems. However, high-throughput data collection and processing
remains non-trivial, making assessment of phenotypes difficult.We describe a platform for surveying the lipid fraction for a range
of tissues. These techniques are demonstrated on a set of seven different tissues (serum, brain, heart, kidney, adipose, liver, and
vastus lateralis muscle) from post-weaning mouse dams that were either obese (> 12 g fat mass) or lean (<5 g fat mass). This
showed that the lipid metabolism in some tissues is affected more by obesity than others. Analysis of human serum (healthy non-
pregnant women and pregnant women at 28 weeks’ gestation) showed that the abundance of several phospholipids differed
between groups. Human placenta from mothers with high and low BMI showed that lean placentae contain less polyunsaturated
lipid. This platform offers a way to map lipid metabolism with immediate application in metabolic research and elsewhere.
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Introduction
Detailed molecular surveys of the lipid fraction of biological
samples (lipidomics) are of increasing interest in research of
metabolism, development, and disease. They offer an insight
into both energy storage, energy distribution, and structural
changes at the membrane level. The power of lipidomic anal-
ysis is increasing further through ongoing development of
techniques for characterizing the lipid fraction of biological
samples [1–5] and has led to the development of a number of
catalogues and databases detailing the known chemical and
physical facets of known phospholipids [6–11].
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There is mounting evidence that lipid metabolism has a
crucial role in growth and metabolic disease in humans
[12–16]. This has encouraged the development of methods
required for lipid profiling. Such studies are typically based
on plasma or serum samples from large numbers of human
participants. With meta-data, this type of sample set can be
used to give a useful snapshot of the metabolic or disease
status of the participants. However, the interest has also led
to questions that cannot be answered by determining the lipid
composition of the circulating plasma or serum alone.
Answering such questions requires an understanding of the
lipid metabolism within and between organs, such as the liver
and brain, across the life-course. This requires lipid profiling
of more than one tissue, often at the same time, from the same
individual animal and even longitudinally.
However, the liver and other such organs contain fibrous
components that make the lipid fraction less accessible than it
is in serum. This fibrosity makes extraction of lipids more
difficult and measurements less consistent. Furthermore,
whole-cell samples typically contain lipases that remain active
ex vivo and can modify the lipids present, corrupting the final
lipid profile acquired [17]. These factors make it yet more
challenging to process tissue samples in a high-throughput
manner, meaning that high-powered studies are less feasible.
This led us to develop a comprehensive pipeline that is
amenable to investigation of lipid metabolism simultaneously
across several tissues. We define pipeline as a series of
methods that encompass all the steps necessary to acquire an
interpretable lipid profile of a tissue sample. In this case, indi-
vidual steps can be used in isolation or replace existing tech-
niques in other pipelines or workflows.
The pipeline we developed was applied to investigate the
lipid profile of two groups of mice (one lean and one obese)
that represent a model of obesity with gestational diabetes
[18–20]. Mouse brain, liver, heart, kidney, vastus lateralis
muscle, and adipose tissue were run in the same sample batch
with serum from the same individual animals. This was used
to produce a set of lipid surveys that characterise the lipid
metabolism in the two groups through their internal systems.
We used human serum samples from both pregnant and non-
pregnant women taking part in an oral glucose tolerance test
(OGTT) to explore the scope of this platform to uncover the
shifts in lipid metabolism within tests of metabolic health, from
a well-established sample type. Blood samples were taken from
pregnant women at 28weeks gestation and non-pregnant healthy
control women (similar age and BMI) at fasting and 2 h after the
glucose challenge. Lastly, we describe analysis of a set of human
placentae from obese and lean women who participated in the
Pregnancy Outcome Prediction (POP) study [21, 22].
A method for extracting the lipid and triglyceride fraction
in a manner that is sympathetic to the chemical sensitivity of
lipids is described and is followed by molecular profiling
using both direct infusion mass spectrometry (DI-MS) and
liquid chromatography with mass spectrometry (LC-MS)
and phosphorus NMR (31P NMR). Methods for processing,
basic analysis, and interpreting these data are then described.
The pipeline is sufficiently flexible to allow for requirements
of a variety of study designs and sizes. For example, we use
31P NMR with the expectation that in most high-powered
studies, sufficient material for a sample will require pooling
of samples from each phenotype.
The pipeline developed can be used on a particular sample type
or as a platform for several sample types using high-throughput
lipidomics, providing data on whole-body lipid profiling.
Materials and methods
Tissue and serum sample acquisition from mice
Mouse tissue samples were taken from post-weaning dams
that were lean or obese. The latter represents a model of pre-
vious GDM [18–20]. Female C57BL/6J mice were randomly
assigned to either a standard chow RM1 diet (approx. 7%
mono/disaccharides, 3% fat, 50% polysaccharide, 15% pro-
tein [w/w], 10.74 kJ/g) or a highly palatable, energy-rich,
s em i - syn t h e t i c obe sogen i c d i e t ( app rox . 10%
mono/disaccharides, 20% animal lard, 28% polysaccharide,
23% protein [w/w], 28.43 kJ/g) supplemented with sweetened
condensed milk (Nestle, UK) (approx. 16% fat, 33%
mono/disaccharides, 15% protein, 13.7 kJ/g) and fortified
with the vitamin and mineral mixture AIN93G. All feeds were
purchased from Special Dietary Services (Witham, UK). After
3 weeks fed ad libitum, females were mated with chow-fed
males (first pregnancy). Dams remained on the same diets
throughout gestation and lactation. The first litter was culled
after they had been weaned. The first pregnancy ensured fer-
tility and nurturing in the experimental mice. Seven days after
weaning, body composition in the female dams was measured
by time-domain nuclear magnetic resonance. As in previous
work, the obese dams’ body composition was around 30–35%
fat and that body weight did not exceed 35 g prior to mating
for the second pregnancy [18]. The control (chow-fed) dams’
body composition was not permitted to exceed 10–12% prior
to mating for the second pregnancy.
Samples of tissues from lean (< 5 g absolute fat mass) and
obese (> 12 g absolute fat mass) post-weaning dams were
used. Mice were culled by increasing the concentration of
carbon dioxide, tissues dissected immediately, flash-frozen,
and stored at − 80 °C. Blood was sampled by cardiac puncture
and the serum obtained, snap-frozen, and stored at −80 °C.
Tissue and serum sample acquisition from humans
Human serum samples came from pregnant (28 weeks’ ges-
tation) and non-pregnant women and were collected at fasting
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(0 h) and 2 h postprandial as part of an oral glucose tolerance
test. Participant data is shown in Electronic Supplementary
Material (ESM) Table S1).
Villous human placenta samples were acquired from the
Pregnancy Outcome Prediction Study (POPS) [22, 23]. All
participants gave written informed consent. Samples from 79
placentae from live, singleton, vaginal births from mothers
who were either lean (BMI 20–24, n = 39) or obese (BMI >
30, n = 40) were used (ESM Table S2).
Chemicals and reagents
Fine chemicals and HPLC-grade solvents were purchased
from Sigma Aldrich-Merck plc (Gillingham, Dorset, UK)
and used without further purification. Phospholipid, sterol,
and triglyceride standards were purchased from Avanti Polar
Lipids (Alabama, USA).
Stock solutions
1. GCTU. Guanidine (6 M guanidinium chloride) and thio-
urea (1·5 M) were dissolved in deionised H2O together
and stored at room temperature out of direct sunlight.
2. DMT. Dichloromethane (3 parts), methanol (1 part) and
triethylammonium chloride (0·0005 parts, i.e. 500 mg/L)
were mixed and stored at room temperature out of direct
sunlight.
3. MS-mix. Propan-2-ol (2 parts) was mixed with methanol
(1 part) and used to produce a solution of CH3COO.NH4
(7·5 mM).
Tissue sample preparation for extraction of the lipid
fraction
Samples of mouse brain, heart, vastus lateralis muscle, liver,
kidney, and adipose tissue and human placenta were proc-
essed into pipettable solutions using GCTU and a hand-held
homogeniser (TissueRuptor II, Qiagen, unless otherwise stat-
ed), see ESM Table S3. Fibrous tissues such as vastus lateralis
benefitted from freeze-thawing. Serum samples were not treat-
ed with GCTU.
Extraction of the lipid fraction
Solutions of homogenised organ preparations (volumes given
in ESM Table S3; calculated to give ~1 μL lipid mixture per
sample extraction) were injected into a well (96-well plate,
Esslab Plate+™, 2·4 mL/well, glass-coated) followed by in-
ternal standards (150 μL, mixture of internal standards in
methanol (see ESM Table S4), water (500 μL), and DMT
(500μL) using a 96-channel pipette. Themixture was agitated
(96-channel pipette) before being centrifuged (3·2 k × g,
2 min). A portion of the organic solution (20 μL) was trans-
ferred to a high-throughput plate (384-well, glass-coated,
Esslab Plate+™) before being dried (N2 (g)). When 4 × 96-
well plates had been placed in the 384 well and the instrument
was available, the dried films were re-dissolved (tertiary--
butylmethyl ether, 20 μL/well, and MS-mix, 80 μL/well)
and the plate was heat-sealed and queued immediately, with
the first injection within 10 min.
Samples with a high concentration of triglycerides (TGs;
e.g. adipose tissue) were treated as follows to concentrate the
phospholipid fraction so it too could be profiled [24]: A sec-
ond portion of the organic phase from the extraction (100 μL)
of was transferred to a shallow plate (96-well, glass-coated)
before being dried (N2 (g)), washed (hexane, 3×100 μL/well),
and re-dissolved (DMT, 30 μL). The samples were transferred
immediately to the high-throughput analytical plate as above
and dried (N2 (g)).
Direct infusion mass spectrometry
All samples were infused into an Exactive Orbitrap (Thermo,
Hemel Hampstead, UK), using a TriVersa NanoMate
(Advion, Ithaca US), for direct infusion mass spectrometry
(DI-MS [16, 25]). Samples (15 μL ea.) were sprayed at 1·
2 kV in the positive ion mode. The Exactive started acquiring
data 20 s after sample aspiration began. The Exactive acquired
data with a scan rate of 1 Hz (resulting in a mass resolution of
100,000 full width at half-maximum [fwhm] at 400 m/z). The
Automatic Gain Control was set to 3,000,000 and the maxi-
mum ion injection time to 50 ms. After 72 s of acquisition in
positive mode the NanoMate and the Exactive switched over
to negative ionisation mode, decreasing the voltage to − 1·
5 kVand the maximum ion injection time to 50 ms. The spray
was maintained for another 66 s, after which the NanoMate
and Exactive switched over to negative mode with in-source
fragmentation (also known as collision-induced dissociation,
CID; 70 eV) for a further 66 s. After this time, the spray was
stopped and the tip discarded, before the analysis of the next
sample began. The sample plate was kept at 15 °C throughout
the acquisition. Samples were run in row order. The instru-
ment was operated in full scan mode from m/z 150–1200 Da
(for singly charged species).
Liquid chromatography-mass spectrometry
LC-MS was run as we described in our recent studies [14, 16,
26, 27], with the additional use of CID for analyses described
here. For all runs, chromatographic separation of lipid and
triglycerides was achieved using a Waters Acquity UPLC
CSH C18 (50 mm × 2·1 mm, 1·7 mm) LC-column with a
Shimadzu UPLC system (Shimadzu UK Limited, Milton
Keynes, UK). The column was maintained at 55 °C with a
flow rate of 0·5 mL/min. A binary mobile phase system was
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used with mobile phase A; acetonitrile:water mix (6:4, respec-
tively, with 10 mM ammonium formate), and mobile phase B;
isopropanol:acetonitrile mix (9:1, respectively, with 10 mM
ammonium formate). Gradient profile: 0 min, 40% mobile
phase B; 0·4 min, 43%mobile phase B; 0·45min, 50%mobile
phase B; 2·4 min, 54%mobile phase B; 2·45min, 70%mobile
phase B; 7 min, 99% mobile phase B; 8 min, 99% mobile
phase B; 8·3 min, 40% mobile phase B; 10 min, 40% mobile
phase B. Mass spectrometry detection was performed on a
Thermo Exactive orbitrap mass spectrometer (Thermo
Scientific, Hemel Hempstead, UK). A heated electrospray
source was used; the sheath gas was set to 40 (arbitrary units),
the aux gas set to 15 (arbitrary units) and the capillary temper-
ature set to 300 °C. The instrument was operated in full scan
mode from m/z 100–1800 Da (for singly charged species).
Lipid species were identified by detecting a signal peak for
the corresponding accurate mass at the correct retention time.
Signals were normalised to the total lipid/glyceride signal for
that sample.
Signals data were collected across three runs. The first op-
erating in positive ion and negative ion continuous switching
mode. This was used for profiling the lipid fraction and quan-
tifying all variables. The second run was a continuous nega-
tive ion mode switching between CID on and off. The third
was a continuous positive ion mode switching between CID
on and off. Runs 2 and 3 were used to identify the fatty acid
composition of individual peaks in the chromatogram, in order
to identify the configuration of the lipid isoform(s) present.
Data handling and processing to produce a full
lipidome
Both the direct infusion and liquid chromatography-mass
spectrometry data are acquired in the form of .RAW files
produced by the Thermo® Xcalibur software. Data from di-
rection infusion mass spectrometry was processed through
automated extraction of the relevant signals using an
established in-house R code [25, 26, 28] and pre-determined
search lists for the positive, negative and high energy negative
(in-source fragmentation/collision-induced dissociation)
ionisation modes used. This produced a list of signals with
accompanying deviations. The first stage of data processing
was to exclude signals that deviated too greatly from the ex-
pected high-resolution mass. The threshold used for devia-
tions was informed by the deviations of the internal standards
(ISs) used. Lipids used as internal standards perform well in at
least one of the two modes; however, several are known to
deviate more than an acceptable amount in one of the two
modes. Thus, plotting the deviations of the IS lipids can be
used to indicate the general deviation of that measurement
period. Generally, a deviation cut-off of 9 ppm is sufficient
for large (> 500) sample sets, where small ones (< 100) can be
settled by a deviation of 5 ppm.
We then carried through variables whose signal intensity
correlated with their concentration. This was determined
through quality control (QC) samples of several types. We
have developed a QCmixture that comprises a comprehensive
range of commercially available mixtures of lipids from bio-
logical sources. We also used QCs of pooled human serum
and mouse serum from the present samples, homogenised
mouse livers, and a mixture of infant formulae and Jerseymilk
previously used [24, 29]. The variables that also had a signal-
to-noise ratio (against IS-containing blank samples) of >3
were then identified. Variables with fewer than 25% values
in any one sample group for each tissue were excluded.
31P NMR
Tissue homogenates were combined to give 5–10 mg of
phospholipid per NMR sample. This approach was used
as it is regarded by us as more generally representative of
high-powered studies in which only a small quantity of
material is available for each participant. The combined
homogenates (~ 5 mL) were diluted with water (10 mL)
and DMT (15 mL) in a Falcon tube (50 mL) before the
mixture was agitated and centrifuged (3·2 k × g, 5 min).
The bulk of the aqueous fraction and the mesophasic solid
were discarded. The organic solution was concentrated to
dryness (N2 (g)) and the resulting film stored at −80 °C.
Samples were dissolved in a modified [5, 30] form of the
‘CUBO ’ solvent system [31–34] (the amount of
dueteriated dimethylformamide d7-DMF was minimised,
to around 20%). Stock solutions of the solvent consisted
of dimethylformamide (3·5 mL), d7-DMF (1·5 mL),
triethylamine (1·5 mL), and guanidinium chloride
(500 mg). Wilmad® 507PP tubes were used. Sample con-
centration was 5–10 mg lipids per sample (600 μL).
Lipid samples were run on a Bruker Avance Neo 800-MHz
spectrometer, equipped with a QCI cryoprobe probe. 1D
Phosphorous experiments were acquired using inverse gated
proton decoupling. Spectra were averaged over 1312 tran-
sients with 3882 complex points with a spectral width of 14·
98 ppm. An overall recovery delay of 8·4 s was used. Data
were processed using an exponential line broadening window
function of 1·5 Hz prior to zero filling to 32,768 points and
Fourier transform. Data were processed and deconvoluted
using TopSpin 4.07. Subsequent integrations above a noise
threshold of 0·01% of the total 31P signal integration were
used to establish the molar quantity of a given phosphorus
environment.
2D (31P-HSQC) spectra were acquired using an XY16-
CMPG sequence for transfer and GARP-4 decoupling. The
direct dimension consisted of 3072 points with 16 transients,
and 2048 points in t1 collected using non-uniform sampling
with a 25% sparsity, giving 256 points overall for the indirect
dimension. Data were processed with compressed sensing,
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linear prediction in F1 and a shifted sine squared window
functions.
Statistical methods
Univariate and bivariate statistical calculations were made
using Microsoft Excel 2016. Multivariate tests were carried
out usingMetaboAnalyst 4.0 [35]. We employed a Bonferroni
correction for dependent variables (0·05/sqrt(n)) as the vari-
ables analysed were highly correlated, e.g. p = 0·0022 for 500
variables. Graphs were prepared in Origin 7.0 or Excel 2016
from mean and standard deviation.
Results and discussion
Design of the pipeline
The design of the pipeline incorporates several novel features
for characterizing the lipid fraction of biological samples at the
molecular level. This pipeline has been used on a set of mouse
tissues (serum, adipose, vastus lateralis muscle, liver, kidney,
brain, and heart) and two human sample types (serum, placen-
ta) in order to indicate its capabilities and where special atten-
tion is required in applying the platform or individual steps to
high-throughput studies.
Preparation of tissue samples
The texture and size of tissues, such as the vastus lateralis
muscle and adipose, and organs such as the heart, liver, pla-
centa and even brain can make handling awkward, especially
if large numbers of samples are required for a high-throughput
study. We have therefore developed a method for preparing
pipettable liquid samples using a solution that is expected to
suppress endogenous lipases and phosphatases [5, 36] and
disrupt intermolecular reactions. We chose bladed homogeni-
sation for ensuring physical disruption of the sample. It was
found to be quicker and produced more consistent results than
a pestle and mortar, and was suitable for all tissues. The con-
tact areas of the blades were cleaned with organic solvents and
then water after each sample homogenisation. Importantly,
each homogenisation took place in the presence of a mixture
of guanidinium chloride (6 M) and thiourea (1·5 M), referred
to here as GCTU. The presence of these powerful chaeotropes
during disruption ensures that cellular structures are disman-
tled at a molecular level and proteins are denatured readily,
suppressing all enzymatic activity. This yielded typically
translucent solutions that were readily pipettable.
The most fibrous tissue (vastus lateralis muscle) benefitted
from freeze-thaw cycles in the appropriate buffer before phys-
ical disturbance. The addition of GCTU was not required for
milk [24, 29], plasma or serum samples (data not shown).
Samples containing particularly high concentrations of tri-
glycerides produced biphasic systems in GCTU, with the up-
per phase containing most of the fat [24]. In order to ensure
that the fattiest solutions were pipettable, we added 0·4 vol-
umes of methanol and 0·2 volumes of tert-butylmethyl ether
to favour formation of a monophasic solution shortly before
sample transfer for extraction.
Extraction of the lipidome
The first widely accepted methods for extracting lipids from
biological samples date from the 1950s and have been used
countless times in the decades since [17]. Simplified forms of
the procedures described by Folch et al. [37] and Bligh &
Dyer [38] remain popular. However, since the chemical and
physical behaviour of lipids has been characterised in detail a
more nuanced understanding of them has emerged. This un-
derstanding suggests that exposing lipids to chloroform can
result in chemical damage and that not all lipids of interest
dissolve well in small quantities of chlorinated solvents
(reviewed in [17]). These observations led us to test several
improvements to the original procedures [5, 29, 30] that we
have developed to produce a method that can be applied to
high-throughput metabolic studies, described here for the first
time.
In order to avoid the chemical damage associated with the
use of chloroform [17] we have used dichloromethane in its
place. We have also used triethylammonium chloride. This
supplies a cation that is soluble in organic solvents and thus
facilitates more polar lipids dissolving in the organic fraction.
The extraction used also has a large enough volume of water
to lower the concentration gradient of the guanidine and thio-
urea between the aqueous and organic phases. This therefore
favours the transfer of lipids into the organic phase and other
components into the aqueous phase.
These steps were incorporated into a procedure that can be
used for extractions of the lipid fraction in a high-throughput
manner.We used a 96-well plate format, with samples injected
into the plate (well volume of 2·4 mL) before sequential ad-
dition of internal standards, water and a solution containing
dichloromethane and triethylammonium chloride. We used a
96 channel pipette (liquid-handling robot, Integra Viaflow 96/
384 channel pipette.), and designed the order of steps to min-
imise biohazard and plastic waste by using just one set of tips.
The biphasic mixtures in each well were agitated in order to
equilibrate the system, before centrifugation to sharpen the
separation of the organic and aqueous phases. The bulk of
the aqueous phase was removed to facilitate access to the
(lower) organic solution. A portion of this was transferred to
a mass spectrometry plate (typically 384 or 96 well) to profile
the whole fraction.
We found subsequently that although this pipeline is satis-
factory for most tissues, high-fat samples such as adipose
A high-throughput platform for detailed lipidomic analysis of a range of mouse and human tissues
tissue, and even jersey milk, typically give mass spectra dom-
inated by triglycerides [24, 29]. This is useful for profiling the
fatty components but it can make surveying the phospholipid
fraction challenging as it is obscured by the abundance of
triglycerides.
This led us to develop a method for removing the bulk of
the triglyceride fraction from such samples in a non-selective
manner. This was achieved by transferring a volume 5× great-
er than that used for the whole-sample profiling, drying and
then washing with petroleum spirit or n-hexane. This dis-
solves the triglycerides but not the phospholipids, meaning
they can be removed with relative ease. This reduces the abun-
dance of triglycerides and increases the number of phospho-
lipid variables observed [29].
Profiling of the lipid fraction using direct infusion mass
spectrometry (DI-MS) with a CID mode
In order to produce a detailed molecular survey in a high-
throughput manner, we have made use of Direct Infusion
Mass Spectrometry (DI-MS) [25, 26, 28, 39]. In this process,
samples in organic solution are injected into the Orbitrap with-
out chromatography and ionised in positive and then negative
modes. This has been used in a variety of studies of human
metabolism [14, 26, 28, 40] as it enables sterols, lipids, and
triglycerides to be profiled, despite very different ionisation
efficiencies. Positive ionisation mode favours triglycerides
(that adopt a positive charge through forming sodium or am-
monium adducts) and phosphatidylcholines (PCs, that have a
‘permanent’ positive charge), where negative ionisation mode
favours anionic phospholipids particularly, still with good sig-
nals from zwitterionic ones such as PC.
This two-part DI-MS method has been used successfully
for several metabolomics studies [16, 25, 26]. In order to
profile the fatty acids (FAs) in the phospholipid fraction, we
have extended this to include a third mode that fragments
species that ionise in negative mode (mainly phospholipids).
This means the fatty acid profile can be determined readily
and without the need for a second technique such as GC-MS
[24, 29]. This is useful in metabolic studies as it can be used to
identify changes in fatty acids associated with de novo lipo-
genesis (shorter, saturated species), and dietary intake, e.g.
essential FAs. The three-part DI-MS method used to establish
the lipidome in positive, negative and FA modes is very ame-
nable to high-throughput studies, with it being possible to run
a 384 well plate in only 32 h [24, 29].
Profiling a subset of samples using liquid
chromatography-mass spectrometry with CID
Liquid chromatography-mass spectrometry (LC-MS) was
used to verify the signals identified in DI-MS [14, 26, 27,
39] and exploit in-source fragmentation (CID) in order to
identify the fatty acids associated with individual lipid vari-
ables. Verification of the existence of signals observed in DI-
MS using LC-MS is scientifically valuable as it provides fur-
ther evidence of the molecular structure of the species identi-
fied. It represents a targeted approach after an untargeted one,
in order to acquire detailed information of a smaller number of
species of greater importance to the hypothesis being tested.
Signals data were collected across three runs. The first op-
erating in positive ion and negative ion continuous switching
mode. This was used for profiling the lipid fraction and quan-
tifying all variables. The second run was a continuous nega-
tive ion mode switching between CID on and off. The third
was a continuous positive ion mode switching between CID
on and off. Runs two and three were used to identify the fatty
acid composition of individual peaks in the chromatogram,
associated with a known variable, in order to identify the
configuration of the lipid isoform(s) present. A combination
of the positive and negative-CID runs was used to determine
the fatty acid profile of isoforms identified in DI-MS and
confirmed by LC-MS. An example of this is shown in Fig.
S1 (see ESM).
PC(36:6) was identified as being present only in the kid-
neys of obese mice. This raises metabolic questions about why
a polyunsaturated lipid should be there, but also what the
configuration is. The precise configuration may shed light
on how obese systems (mis)manage the distribution of
PUFA-containing lipids. We used a combination of LC-MS
with both positive ionisation and negative ionisation mode
with CID switching to identify fragments at the appropriate
retention time, for this lipid. This showed clearly that
PC(36:6) was PC(14:0/22:6) (ESM Fig. S1). This suggests
that in obese systems, at least one essential fatty acid contain-
ing lipid is transported to the kidney in a way that does not
occur in lean mice.
We also used this approach to quantify how a mixture of
configurations differs according to phenotype. PC(38:5) is
evident in the hearts of both lean and obese mice. However,
a number of configurations are possible. We found that this
lipid consists of trace amounts of PC(16:0/22:5), with most of
the signal being ascribed to either PC(20:3/18:2) or PC(20:2/
18:3). However, the proportion appears to change, with
PC(20:3/18:2) being around 10% more abundant in the hearts
of obese mice than lean ones. This approach therefore offers a
way of characterising the lipid profile of different phenotypes
and tissues in detail.
Signal identification using dual spectroscopy
Mass spectrometry has proved a very useful tool in lipidomics
and will remain the main technology used in this discipline for
high-throughput studies. It is possible to acquire large
amounts of information and quantify the abundance of hun-
dreds of lipids from relatively small samples using this
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technique. The availability of three ionisation modes as shown
here has extended the range of species that can be observed in
one DI-MS method. However, inherent in this technique is
that positive and negative ionisation modes offer different
ionisation efficiencies. Triglycerides and phosphatidylcho-
lines ionise efficiently in positive ionisation mode and anionic
phospholipids, especially lyso-lipids ionise particularly well in
negative ionisation mode.
This can however make accurate quantification of lipid
variables difficult and restricts automation of the process.
Furthermore, there is no standard approach to signal identifi-
cation. Some approaches are relaxed, meaning the bulk of the
‘true’ signals are identified, but also noise can be incorrectly
identified as a signal. There appear to be several examples of
this in the recent literature, with quite unrealistic assignments
being made in some cases. Some approaches are more con-
servative, in which mis-identification is much less common
but where real signals may be missed. Neither of these ap-
proaches is objectively better as they both risk arriving at an
incorrect answer.
In this study, we have addressed questions about reliable
signal identification and ionisation efficiency of lipid classes
by using 31P NMR. This second, orthogonal, technique shows
the relative abundance of the chemical environments of the
phosphorus atom in the phospholipid head group and thus
gives an insight into the relative ionisation efficiency of lipid
head groups in mass spectrometric measurements. This tech-
nique is therefore a useful ‘reality check’. The technique
comes with its own limits, one of which is that considerably
more material is required for a 31P NMR sample than an MS
one. This means that in most high-powered studies, several
samples from each phenotype or group should be pooled to
produce a large enough sample for practical 31P acquisition.
The approach of using two or more orthogonal techniques for
structural determination has been common practice in synthet-
ic chemistry for some years, but has entered lipidomics more
recently [5, 30]. Dual spectroscopy therefore offers a circum-
spect but well-supported approach to lipidomics.
An independent measure of the ratio of the relative abun-
dance of head groups can be useful for both distinguishing
gross changes between phenotypes as well as for producing
‘rules of thumb’ in assigning IDs to signals in mass spectrom-
etry. Even marginal differences in phospholipid abundance
between groups can be observed using 31P NMR. This is
indicated by a comparison of lean and obese kidney lipid
extracts (ESM Fig. S2). One clear rule of thumb comes from
serum samples. 31P NMR reveals that in serum, phosphatidyl-
ethanolamine (PE) has an abundance around two orders of
magnitude lower than that of phosphatidylcholine (PC, ESM
Fig. S3). This suggests that an abundant variable with an m/z
consistent with a PE should either be given an alternative
assignment (is an isobar) or ionises better than the expected
variable. For example, when a signal that represents the m/z
for both an isoform of phosphatidylethanolamine, PE(38:2)
and one of phosphatidylcholine PC(35:2) is recorded (m/z
772·5851, proton adduct) in a serum sample, the balance of
probabilities rests with it being an isoform of PC rather than a
PE, even for relatively low-abundance configurations that
comprise a fatty acid residue with an odd number of carbons.
This can be supported by analysis using mass spectrometry in
negative ionisation mode. PEs ionise easily as they can be
deprotonated to form a negatively charged species.
However, PCs have a ‘permanent’ positive charge by virtue
of their quaternary amine, a feature that must be masked be-
fore it can adopt an overall negative charge. This confers a
difference in mass on ionised PCs and PEs in negative mode,
meaning they can be distinguished.
31P NMRwas used to gain further insight into the profile of
lipid classes in the samples of interest and even some of the
phenotypes (see Figs. S2, S3, S9, and supplementary spectra
in ESM), and was used to inform the mass spectra used in the
present study. This included respect for the abundance of PE
with respect to isobaric PC but also the abundance of lipids
such as phosphatidic acid, and phosphatidylserine and
phosphatidylglycerol.
The ability to assign signals to resonances is essential for
the successful use of 31P NMR in lipidomics. The existence of
more than one resonance for PE in the present solvent system
has been reported at least three times [5, 30, 34], described as
being due to interaction of this lipid with ion is in the solvent
system (triethylammonium, guanidinium, and metal ions be-
ing the most likely).We therefore used two-dimensional NMR
(31P-HSQC) to look further into the structures of the reso-
nances observed in an attempt to assign themmore accurately.
This analysis (ESM Fig. S4) indicated that PE does indeed
have several phosphorus resonances (0·55, 0·30, 0·15 ppm)
with plasmalogen PC located at around 0·05 ppm, contrary to
some previous reports. Furthermore, investigation using 31P-
HSQC suggested to us that there may also be more than one
resonance for PC, though with more similar shifts than are
observed for PE such that they are not typically separated,
e.g. mouse kidney samples (0·0 ppm, see Fig. S2 and supple-
mentary spectra in ESM). This approach may be useful to
interpret otherwise unclear spectra and thus contribute to-
wards an accurate phospholipid profile.
Lipidome analysis
Semi-quantitative and quantitative lipidomics data on a varie-
ty of tissues from a group of individuals associated with a
particular phenotype (such as obesity) offers a unique oppor-
tunity to characterise that phenotype. In particular, the locus of
changes in lipid metabolism can be rapidly assessed in a way
that is not possible from serum samples alone. Here, we dis-
cuss three simple analyses for determining differences
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between phenotypes: (a) abundance analysis, (b) fatty acid
biosynthesis, (c) candidate biomarker discovery.
Simple plots of abundance can be used as a tool for deter-
mining which tissues are of principal interest for a given phe-
notype. For example, in the present mouse obesity phenotype,
liver is changed considerably (ESM Fig. S5A) but brain ap-
pears to be little changed (ESM Fig. S5B). Specifically, pro-
files of the liver of lean and obese post-weaning dams showed
that the abundance of triglycerides was much higher in tissues
from obese individuals. We therefore suggest that this calcu-
lation is useful for identifying the tissues of greatest interest
for characterizing the lipid metabolism in a particular
phenotype.
An abundance analysis using values across samples, for
example of fatty acids, can also be revealing. The fatty acid
profile of phospholipids was acquired using DI-MS (vide
supra) though negative ionisation with CID. We found that
several fatty acids differed in abundance in the hearts of lean
and obese dams (Fig. 1). These results are interesting for met-
abolic study as they suggest that FA(16:0), an established
marker of de novo lipogenesis (DNL), is more abundant in
obese mice. This suggests that DNL is different between these
two systems and that the lipid composition of the heart reflects
this. This analysis also uncovers the pattern that odd-chain
fatty acid residues are more abundant in the hearts of lean
mice. These results are interpretable in terms of the aetiology
of metabolic and heart disease [24, 41–44] in a manner that is
orthogonal to the abundance analysis of whole lipids.
Abundance analysis can be used to indicate general chang-
es in lipid metabolism. The same lipid data from several tis-
sues from the same individual with a particular phenotype that
are analysed simultaneously can also be used to identify
changes in the activity of individual enzymes associated with
lipid metabolism. For example, comparing the ratio of partic-
ular lipids to one another can be used to infer the activity of
particular enzymes involved in fatty acid biosynthesis and
modification. A variety of lipid abundance ratios have been
used for this, either using the ratio of particular fatty acids or
lipids that comprise them: fatty acid elongase (FA(18:0)/
FA(16:0); PC(36:4)/PC(34:2)) [45–47], Stearoyl co-acetyl
desaturase (CE(16:1)/CE(16:0); CE(18:3)/CE(18:2);
PC(32:1)/PC/32:0)) [48, 49], fatty acid desaturase 1
(FADS1, PC(38:4)/PC(38:3); TG(54:4)/TG(54:3)) [45, 46],
and fatty acid desaturase 2 (FADS2, PC(36:3)/PC(36:2);
TG(50:3)/TG(50:2)) [45, 46].
We calculated the ratio of TG(50:2) to TG(50:3) for both
lean and obese mice as a marker of FADS2 activity (ESM Fig.
S6). This showed that the ratio of these two lipids was similar
in the adipose of lean and obese mice. However, lipid profiles
from brain and liver show that the ratio of TG(50:2) to
TG(50:3) was higher in lean mice than in obese ones, with
the opposite true in kidney, serum, heart, and vastus muscle.
This suggests that FADS2 activity is modulated in obese
individuals.
Discovery of candidate biomarkers (CBMs) is an
established technique for identifying the variables that both
distinguish two groups and drive the statistical difference be-
tween them [13, 16, 24, 26]. This involves running a sparse
partial least squares discriminant analysis [35] followed by a
student’s t test with a significance threshold adjusted for mul-
tiple variables and/or comparisons as appropriate.
Most studies in which CBM discovery has been employed
have used plasma or serum samples. We tested our lipidomics
pipeline on a modest set of human sera from pregnant (n = 12,
28 weeks gestation) and non-pregnant (n = 10) women at both
the fasting and 2 h time points of the oral glucose tolerance test
(OGTT). The 2 h time point is the time after ingesting glucose
(75 g). The frozen serum samples were thawed and the lipid
fraction extracted from samples in a high-throughput manner,
a
b
Fig. 1 The fatty acid residues from phospholipids from the brains (top
panel, a) hearts (bottom panel, b) of lean and obese mice. All variables
differed significantly in hearts (marked *, false-discovery rate-adjusted p
value based on Bonferroni calculation with dependent variables), but
none did in brains. Fatty acids detected and quantified (relative quantifi-
cation) measured using mass spectrometry in negative ionisation mode
with collision-induced dissociation. Error bars show standard deviation
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followed by DI-MS. Paired analyses of the fasting and 2 h
samples of both the pregnant and non-pregnant groups sug-
gested that just one variable, m/z 824·5447 (negative
ionisation mode), differed significantly between the groups.
This m/z is ascribed either to PC(36:5) with a formate adduct,
PC(35:5) with an acetate adduct or possibly deprotonated
PS(39:4) in negative ionisation mode. This subtle difference
between 0 h and 2 h samples is reflected in the comparison
between pregnant and non-pregnant samples made by a
Principal Component Analysis (ESM Fig. S7). The latter anal-
ysis indicated that pregnant and non-pregnant systems differ
considerably in their lipid metabolism, consistent with previ-
ous work [50, 51], that the variables that distinguished fasting
and postprandial samples from pregnant participants are dif-
ferent to those that distinguish fasting and postprandial sam-
ples from non-pregnant women (PC2).
However, (unpaired) comparisons of pregnant and non-
pregnant groups at fasting and 2 h showed that a considerable
number of variables differed in abundance between the two
groups (ESM Fig. S8). This suggests that even with relatively
low statistical power, a number of trends in lipid metabolism
that distinguish pregnant and non-pregnant women are visible
(ESM Fig. S8). This includes a general shortening of the chain
lengths of fatty acids in phosphatidylglycerol (PG), a shorten-
ing of fatty acid chains and reduction in the number of unsat-
urated bonds in both PEs and PC plasmalogens. The abun-
dance of isoforms of phosphatidylinositol (PI) associated with
signalling inositides is reduced in the circulation of pregnant
women. The 31P NMR results (ESM Fig. S3) show that there
is an increase in the relative abundance of (minor lipids) PI
and plasmalogen PC, and a more marked increase in
sphingomyelin (SM), but that PC is still dominant and has
the same ratio with lyso-PC in both phenotypes. There is little
evidence of a major change in the overall relative abundance
of PE. This suggests that although the PEs appear abundant in
negative mode, and the fatty acid profile of the PE fraction
changes significantly, the overall abundance of PE, PC, and
lyso-PC does not change markedly.
The interest in the role of lipid metabolism in human de-
velopment has led to an interest in extracting and profiling
lipids from other human tissues, including more fibrous ones
such as placenta. We sought to characterise the shift in metab-
olism associated with obesity in mothers by searching for
biomarkers that differentiate human placenta samples.
Candidate biomarker discovery found that six lipid species
both differed significantly (p value corrected for multiple var-
iables, based on 455 variables) and were identified as
distinguishing the two phenotypes using an sPLS-DA, all of
which were phospholipids (Fig. 2).
This approach indicates that two polyunsaturated lipids
comprising two fatty acid residues (PC(36:4), PE(38:6)) are
less abundant in lean placentae. This is remarkable as
PC(36:4) represents ~ 15% of the total lipidome as measured
in positive ionisation mode. Saturated or mono-unsaturated-
containing species (PC-O(40:0), PE(36:2), SM(38:1)) are
more abundant. lyso-PC(20:4), a possible degradation product
of PC(36:4) and marker of a variety of metabolic changes, is
also more abundant in obese placentae. These observations
indicate that the metabolism of phospholipids, at least one of
which can be regarded as very abundant in this lipidome, is
altered in obesity.
These data indicate that in general, lipidomics of mem-
branes in obese placentae differ across at least two lipid
biosynthesis pathways. This modulation in composition
raises questions about the physical behaviour of such
membranes. Studies of the mesophase behaviour of lipid
systems [52] and of the role of PE in biological systems
[53] suggest that changes to PC and PE composition can
have profound effects on the behaviour of such systems.
The higher abundance of the fluidising PC(36:4) in obese
placentae suggests that membranes in those placentae may
be more fluid than those in lean ones. However, the ratio of
total PE to PC indicates that there is in general more PE in
lean placentae (measured in positive ionisation mode, p =
0·0003). This is reflected in pooled human placenta sam-
ples subjected to 31P NMR, where the abundance of PE
appears to be slightly higher in lean placentae (ESM Fig.
S9). This suggests that the biophysical behaviour as well as
the lipid metabolism differs in lean and obese human pla-
centae. Furthermore, 31P NMR also indicates that globally,
there may also be slightly more PI and SM in lean placen-
tae, also expected to have an impact on mesophase
Fig. 2 Candidate biomarkers that represent differences in lipid
metabolism in lean and obese placentae, from term singleton
pregnancies collected in the Pregnancy Outcome Prediction Study.
Variables shown represented those that distinguished the two
phenotypes (lean/obese) and were significant (pass at false-discovery
rate-adjusted p value [Bonferroni FDR correction for many dependent
variables])
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behaviour [54, 54]. This type of analysis, on a pilot-sized
group (n = 79), can be used to inform how lipid metabo-
lism in placentae is investigated in a larger sample set.
Conclusions
The platform described here provides methods that can be
used individually in existing procedures or in series to facili-
tate characterisation of the lipid fraction of biological samples.
The analysis of a set of mammalian tissues from lean and
obese mice demonstrates that the access to the lipid fraction
of a variety of tissues enables researchers to answer questions
and test hypotheses that hitherto had too high an experimental
barrier to overcome. This is particularly useful for metabolic
studies as it allows the effect of phenotypes such as obesity to
be understood in different organ systems, and thus compared.
The depth and breadth of this approach to lipidomics paves the
way for the development of bioinformatics tools focused on
lipid metabolism.
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